Overview

Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation

Status:
Not yet recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2 study evaluating the positron-emitting radiopharmaceutical 18F-mFBG as an imaging agent for quantification of myocardial sympathetic innervation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Illumina Radiopharmaceuticals, LLC
Collaborator:
Icahn School of Medicine at Mount Sinai